PL373523A1 - Indol-2-ony jako selektywne inhibitory cyklooksygenazy-2 - Google Patents

Indol-2-ony jako selektywne inhibitory cyklooksygenazy-2

Info

Publication number
PL373523A1
PL373523A1 PL03373523A PL37352303A PL373523A1 PL 373523 A1 PL373523 A1 PL 373523A1 PL 03373523 A PL03373523 A PL 03373523A PL 37352303 A PL37352303 A PL 37352303A PL 373523 A1 PL373523 A1 PL 373523A1
Authority
PL
Poland
Prior art keywords
cyclooxygenase
indol
ones
selective inhibitors
inhibitors
Prior art date
Application number
PL03373523A
Other languages
English (en)
Inventor
Kristin Lundy Demello
Brian Scott Bronk
Rhonda Marie Crosson
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29251180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL373523(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL373523A1 publication Critical patent/PL373523A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL03373523A 2002-04-22 2003-04-10 Indol-2-ony jako selektywne inhibitory cyklooksygenazy-2 PL373523A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37437202P 2002-04-22 2002-04-22

Publications (1)

Publication Number Publication Date
PL373523A1 true PL373523A1 (pl) 2005-09-05

Family

ID=29251180

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03373523A PL373523A1 (pl) 2002-04-22 2003-04-10 Indol-2-ony jako selektywne inhibitory cyklooksygenazy-2

Country Status (13)

Country Link
US (1) US6846818B2 (pl)
EP (1) EP1497280A1 (pl)
JP (1) JP2005535576A (pl)
AR (1) AR039320A1 (pl)
AU (1) AU2003215867A1 (pl)
BR (1) BR0309412A (pl)
CA (1) CA2484017A1 (pl)
GT (1) GT200300083A (pl)
MX (1) MXPA04010397A (pl)
PA (1) PA8571601A1 (pl)
PL (1) PL373523A1 (pl)
TW (1) TW200406405A (pl)
WO (1) WO2003089427A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
JP2007532562A (ja) 2004-04-07 2007-11-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション，インコーポレイティド グルコサミン、及びグルコサミン／抗炎症薬の相互プロドラッグ、組成物、及び方法
US8034796B2 (en) * 2004-04-07 2011-10-11 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
JP2009525269A (ja) 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
RU2582278C2 (ru) * 2013-04-25 2016-04-20 Закрытое Акционерное Общество "Фармфирма "Сотекс" Трансдермальное средство для лечения и профилактики болезней суставов и мягких тканей, способ его получения и комбинированный трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160032A (en) 1973-11-21 1979-07-03 Sandoz, Inc. Oxindoles as sleep-inducers
US4006161A (en) 1973-12-26 1977-02-01 Eli Lilly And Company Thio-substituted 2-oxo-indolines
US3882236A (en) 1973-12-26 1975-05-06 Lilly Co Eli Pharmaceutical compositions containing substituted 2-oxo-indolines and the use thereof to treat anxiety and tension
US4569942A (en) * 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
US5047554A (en) * 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
US6048850A (en) 1992-09-22 2000-04-11 Young; Donald A. Method of inhibiting prostaglandin synthesis in a human host
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5434178A (en) 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
EP0826685A1 (en) 1996-08-21 1998-03-04 Pfizer Inc. Stable, long acting salts of carboxamides for the treatment of joint disease

Also Published As

Publication number Publication date
MXPA04010397A (es) 2005-02-17
US6846818B2 (en) 2005-01-25
TW200406405A (en) 2004-05-01
BR0309412A (pt) 2005-02-01
CA2484017A1 (en) 2003-10-30
PA8571601A1 (es) 2003-12-10
GT200300083A (es) 2004-03-29
AR039320A1 (es) 2005-02-16
US20030207897A1 (en) 2003-11-06
AU2003215867A1 (en) 2003-11-03
WO2003089427A1 (en) 2003-10-30
EP1497280A1 (en) 2005-01-19
JP2005535576A (ja) 2005-11-24

Similar Documents

Publication Publication Date Title
EP1549316A4 (en) HAMMER OF TFGbeta
EG25482A (en) Inhibitors
GB0325192D0 (en) Method of use
AU2003261434A8 (en) Iminothiazolidinones as inhibitors of hcv replication
ZA200605348B (en) Solid forms of anti-EGFR-antibodies
HUP0600294A2 (en) Skin-permeable selective cyclooxygenase-2 inhibitor composition
IL169691A0 (en) Malonamide derivatives as gamma-secretase inhibitors
PL373146A1 (pl) Pochodne pirydazynonu jako inhibitory PDE4
PL374279A1 (pl) Nitrooksypochodne inhibitorów cyklooksygenazy-2
AU2003238042A1 (en) Cyclooxygenase-2 inhibitors
EP1577280A4 (en) DEUTERATION PROCESS
ZA200409686B (en) Bicyclic 6-aklylidene-penems as ?-lactamases inhibitors
GB0313668D0 (en) Method of containing peas
PL373523A1 (pl) Indol-2-ony jako selektywne inhibitory cyklooksygenazy-2
EP1488046A4 (en) CONSTRUCTION METHODS
AU2003242559A8 (en) Alkylaminosiloxanes as corrosion inhibitors
GB0311195D0 (en) Glyoxalase inhibitors
AU2003268292A8 (en) Inhibitors of post-amadori advanced glycation end products
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
IL176473A0 (en) Neutrophilia inhibitor
AU2003257060A8 (en) Cyclooxygenase-2 inhibitors for appetite suppression
AU2003215235A8 (en) Cks1 inhibitors
PL356853A1 (pl) Zastosowanie bakteriofagów
GB0423692D0 (en) Method of communicating
GB0329869D0 (en) Inhibitors

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)